Calidi Biotherapeutics, Inc.
CLDI
$1.59
$0.053.25%
AMEX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 9.47M | 10.50M | 10.61M | 10.99M | 11.53M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 19.37M | 20.24M | 19.80M | 19.98M | 20.09M |
| Operating Income | -19.37M | -20.24M | -19.80M | -19.98M | -20.09M |
| Income Before Tax | -19.09M | -20.05M | -20.13M | -20.03M | -20.03M |
| Income Tax Expenses | 16.00K | 15.00K | 20.00K | 9.00K | 13.00K |
| Earnings from Continuing Operations | -19.11 | -20.06 | -20.15 | -20.04 | -20.05 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 81.00K | 157.00K | 205.00K | 188.00K | 142.00K |
| Net Income | -19.03M | -19.91M | -19.95M | -19.85M | -19.90M |
| EBIT | -19.37M | -20.24M | -19.80M | -19.98M | -20.09M |
| EBITDA | -16.80M | -17.70M | -17.29M | -17.48M | -17.65M |
| EPS Basic | -83.04 | -111.53 | -153.91 | -242.65 | -478.90 |
| Normalized Basic EPS | -40.21 | -58.10 | -83.98 | -150.94 | -260.90 |
| EPS Diluted | -83.04 | -111.53 | -153.91 | -242.65 | -478.90 |
| Normalized Diluted EPS | -40.21 | -58.10 | -83.98 | -150.94 | -260.90 |
| Average Basic Shares Outstanding | 1.58M | 1.07M | 707.20K | 441.30K | 289.30K |
| Average Diluted Shares Outstanding | 1.58M | 1.07M | 707.20K | 441.30K | 289.30K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |